OBJECTIVES: To present 2-year results on treatments prescribed and their impact on quality of life (QoL) and clinical severity of children with Attention Deficit / Hyperactivity Disorder (ADHD). METHODS: ADORE is a 2-year, prospective, international observational study in ADHD. Treatments were classified as pharmacotherapy, psychotherapy, pharmacotherapy and psychotherapy combination, other, and none. As patients were allowed to change treatment, different patients may be included in each group at different endpoints. QoL was measured with the Child Health and Illness Profile (CHIP-CE). Clinical ADHD outcomes were measured with ADHD-Rating scale parent version (ADHD-RS), CGI- Severity scale, Children's Global Assessment Scale (CGAS) and Strengths and Difficulties Questionnaire (SDQ). Changes in outcomes presented hereafter were estimated on all patients followed 2 years and having at least baseline and 24 months visits. RESULTS: Among 255 French patients eligible for analysis, mean age (SD) 8.8 years (2.3), 87.5% male, 137 (53.7%) were followed over 24 months. Treatments were respectively at baseline and 2 years: pharmacotherapy 23.0%&29.1%, combination pharmacotherapy/psychotherapy 36.6% & 47.0%, psychotherapy 27.2% & 12.7%, other treatment 4.7% &3.0% and none 8.5% &8.2%. Between baseline and 2 years, CHIP-CE quality of life improved: mean change from baseline was +5.7 (12.9) for satisfaction, +8.6(11.8) for achievement, +13.4(13.0) for risk avoidance, +5.2 (12.4) for resilience and +5.2 (9.6) for comfort. Between baseline and 2 years, mean ADHD-RS change was -18.3(9.9) leading to a final score of 21.4(10.7) at 2 years. CGAS mean change was +15.8 (15.5) leading to a final score of 67.1(16.2). Mean CGI-S change was -1.5 (1.4) leading to a final score of 3.2(1.3). Rate of patients with ³1 comorbidity decreased from 76.5% to 54.0% and severity of comorbidities also decreased. CONCLUSIONS: After 2 years, French patients suffering from ADHD symptoms enrolled in this study benefited from improvement of QoL and clinical severity. Interpretation is difficult due to patients changing treatments over the study.